Identifying customer experiences that drive tool and brand differentiation to help a major tech company build a comprehensive AI brand strategy
Global markets are evolving day by day. Let competitors swoop in first, and your growth opportunities get harder to find. Businesses need to know where to play and how to win. They need comprehensive and predictive global market opportunity assessments for successful new market entry. Be ready for your next window of opportunity.
New market entry is a game of high risk, high reward. A brand’s formula for success in one geography or category can backfire in another. A host of factors are at play with any new market entry. Market-specific economic drivers can impact buying power and price sensitivity. Complex social and cultural forces shape perception and behavior. Not to mention government and regulatory hurdles, intricate distribution ecosystems, and well-established competitors in your way.
Escalent helps expansion-focused brands reformulate for success. We closely assess opportunity and hedge risk with an all-encompassing, geographically nuanced market assessment to inform your next strategic market entry.
Using multiple methodologies and data sources, Escalent gives you a comprehensive view of risk and reward. We’ll often start with a customized assessment of market potential. The assessment looks at many market factors in conjunction with your core brand proposition, product benefits, and your ability to deliver in the market. We consider a mix of market externalities and your business strengths to recommend priority target markets. So, you’ll know where to play and how to win.
And it’s not all about new market entry. Escalent’s framework is designed to help you defend your existing markets from challengers looking to steal share.
Ask about our strategic market assessment and new market entry support.
Using The Advisor Exchange, we conducted our own activity to dive into advisors use and perceptions on private markets.
Explore how emerging women’s health trends—from advanced gut-hormone science to fertility tech and whole-life mental wellness—will reshape pharma in 2026, and what it means for insight leaders tasked with turning deeper, more dynamic patient understanding into impact.
As financial advisors seek to spend more time on business development, new data from Cogent Syndicated reveal that three in ten advisors plan to rely more on model portfolios over the next year.
New Escalent data reveals the number of "technical" advisors has dropped to 36% as professionals focus on client acquisition
New research from Escalent shows one quarter of DC advisors likely to recommend alternatives, with National, large-scale producers driving the trend
Escalent’s 2025 Investor Brand Build™ report highlights the shifting investment landscape, dominated by more diverse, digitally fluent and opportunity-driven affluent investors
